NovoCure Beheer

Beheer criteriumcontroles 2/4

De CEO NovoCure is Asaf Danziger, benoemd in Jan2002, heeft een ambtstermijn van 21.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.28M, bestaande uit 36.4% salaris en 63.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.013% van de aandelen van het bedrijf, ter waarde MX$ 3.55M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 6.1 jaar.

Belangrijke informatie

Asaf Danziger

Algemeen directeur

US$2.3m

Totale compensatie

Percentage CEO-salaris	36.4%
Dienstverband CEO	21.9yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Asaf Danziger's beloning veranderd ten opzichte van NovoCure's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$197m
Jun 30 2023	n/a	n/a	-US$174m
Mar 31 2023	n/a	n/a	-US$141m
Dec 31 2022	US$2m	US$831k	-US$93m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$68m
Mar 31 2022	n/a	n/a	-US$59m
Dec 31 2021	US$1m	US$876k	-US$58m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	US$12m
Dec 31 2020	US$9m	US$782k	US$20m
Sep 30 2020	n/a	n/a	US$19m
Jun 30 2020	n/a	n/a	US$12m
Mar 31 2020	n/a	n/a	US$9m
Dec 31 2019	US$7m	US$702k	-US$7m
Sep 30 2019	n/a	n/a	-US$27m
Jun 30 2019	n/a	n/a	-US$41m
Mar 31 2019	n/a	n/a	-US$55m
Dec 31 2018	US$5m	US$693k	-US$64m
Sep 30 2018	n/a	n/a	-US$59m
Jun 30 2018	n/a	n/a	-US$59m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$4m	US$698k	-US$62m
Sep 30 2017	n/a	n/a	-US$73m
Jun 30 2017	n/a	n/a	-US$95m
Mar 31 2017	n/a	n/a	-US$114m
Dec 31 2016	US$2m	US$651k	-US$132m

Compensatie versus markt: De totale vergoeding ($USD 2.28M ) Asaf } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de MX markt ($USD 697.70K ).

Compensatie versus inkomsten: De vergoeding van Asaf is gestegen terwijl het bedrijf verliesgevend is.

CEO

Asaf Danziger (57 yo)

21.9yrs

Tenure

US$2,278,951

Compensatie

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Doyle	Executive Chairman	19.9yrs	US$2.15m	0.52% MX$ 139.7m
Asaf Danziger	President	21.9yrs	US$2.28m	0.013% MX$ 3.5m
Ashley Cordova	Chief Financial Officer	3.3yrs	US$6.84m	0.067% MX$ 18.0m
Wilhelmus C. Groenhuysen	Chief Operating Officer	3.3yrs	US$6.62m	0.16% MX$ 42.9m
Pritesh Shah	Chief Growth Officer	no data	US$6.32m	0.082% MX$ 22.1m
Frank Leonard	President of CNS Cancers U.S.	3.3yrs	US$6.13m	0.051% MX$ 13.8m
Yoram Palti	Founder & CTO	23.9yrs	US$282.51k	geen gegevens
Moshe Giladi	Chief Science Officer	less than a year	geen gegevens	0.0066% MX$ 1.8m
Ingrid Goldberg	VP of Investor Relations	no data	geen gegevens	geen gegevens
Barak Arye	General Counsel	1.7yrs	geen gegevens	0.0049% MX$ 1.3m
Michael Puri	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
Uri Weinberg	Chief Innovation Officer	less than a year	geen gegevens	0.057% MX$ 15.5m

3.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NVCR N wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
William Doyle	Executive Chairman	19.9yrs	US$2.15m	0.52% MX$ 139.7m
Asaf Danziger	President	11.9yrs	US$2.28m	0.013% MX$ 3.5m
Jeryl Hilleman	Independent Director	5.4yrs	US$445.20k	0.0024% MX$ 642.1k
David Hung	Independent Director	5.6yrs	US$425.09k	0.0063% MX$ 1.7m
Timothy Scannell	Independent Director	2.8yrs	US$439.44k	0.000070% MX$ 19.0k
Kinyip Leung	Independent Director	12.2yrs	US$432.70k	0.070% MX$ 19.1m
William Vernon	Lead Independent Director	17.9yrs	US$481.54k	0.15% MX$ 41.1m
Martin Madden	Independent Director	6.6yrs	US$446.26k	0.015% MX$ 4.0m
Kristin Stafford	Independent Director	less than a year	geen gegevens	geen gegevens
Allyson Ocean	Independent Director	less than a year	geen gegevens	geen gegevens

6.1yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NVCR N wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

NovoCure Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited Announces Executive Changes

Chief Financial Officer recently sold Mex$589k worth of stock

Recent updates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

NovoCure Limited Appoints Christoph Brackmann as Senior Financial Advisor

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd